Documentos de Parkhomenko A.N. | REDI

Regresar

Mostrando 3 resultados de: 3

Filtros aplicados

Área temáticas: "Fisiología humana"

Subtipo de publicación

Publisher

European Heart Journal(1)

Journal of the American College of Cardiology(1)

New England Journal of Medicine(1)

Área temáticas

Enfermedades(3)

Salud y seguridad personal(2)

Medicina y salud(1)

Área de conocimiento

Enfermedad cardiovascular(3)

Medicina interna(3)

Año de Publicación

Origen

Palabras Claves

Cardiovascular disease(1)

PCSK9 inhibitor(1)

Primary Prevention(1)

acute coronary syndrome(1)

lipoprotein(a)(1)

Blood-pressure and cholesterol lowering in persons without cardiovascular disease

Abstract: BACKGROUND Elevated blood pressure and elevated low-density lipoprotein (LDL) cholesterol increase t

Palabras claves:

Accini J.L., Avezum A.J., Bosch J.J., Chazova I.E., Dagenais G.R., Dans A.M., DIaz R., Held C., Jansky P., Jung H., Keltai K., Keltai M., Khunti K., Leiter L.A., Lewis B.S., Liu L., Lonn E.M., McKelvie R., Pais P., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Peters R.J.G., Piegas L.S., Pogue J., Reid C.M., Sliwa K., Toff W.D., Varigos J.D., Xavier D., Yusoff K., Yusuf S., Zhu J.

Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: Results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants

Abstract: Aims: Rosuvastatin (10 mg per day) compared with placebo reduced major adverse cardiovascular (CV) e

Palabras claves:

Cardiovascular disease, Primary Prevention, statins

Avezum A.J., Bosch J.J., Dagenais G.R., Dans A.M., DIaz R., Held C., Jansky P., Joseph P.G., Jung H., Keltai K., Keltai M., Khunti K., Leiter L.A., Lewis B.S., Liu L., Lonn E.M., Pais P., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Peters R.J.G., Piegas L.S., Reid C.M., Sliwa K., Toff W.D., Varigos J.D., Xavier D., Yusoff K., Yusuf S., Zhu J.

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Abstract: Background: Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for m

Palabras claves:

acute coronary syndrome, lipoprotein(a), low-density lipoprotein cholesterol, PCSK9 inhibitor

Alexander J.H., Alexander K., Alings M., Armaganijan L., Aylward P.E., Bagai A., Bahit M.C., Bhatt D.L., Bittner V.A., Brennan J.M., Budaj A.J., Chaitman B., Chiang C.E., Chua T., Chumburidze V., Clifton S., Correa Flores R.M., Dalby A.J., Danchin N., De Silva H.A., Deloatch S., Devore A.D., DIaz R., Dickey S., Dilic M., Dombrowski K., Dorobantu M., Drexel H., Edelberg J.M., Erglis A., Fras Z., Goodman S.G., Gotcheva N.N., Guneri S., Hagström E., Halvorsen S., Hanotin C., Harrington R.A., Jukema J.W., Karpov Y., Kedev S., Kelsey S.F., Kim H.S., Kim S.H., Kimura T., Kiss R.G., Landmesser U., Laucevicius A., Lecorps G., Liberopoulos E., Lopes R.D., Mahaffey K.W., Manvelian G., Marx N., Meloni C., Montenegro Valdovinos P.C., Morais J., Moriarty P.M., Moryusef A., Müller C.E., Murin J., Nieminen M.S., Olsson A.G., Ostadal P., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Pecin I., Pordy R., Poulsen S.H., Prieto J.C., Ramos López G.A., Ray K.K., Reiner Z., Ristic A.D., Roe M.T., Rosenson R., Rouleau J.L., Sasiela W.J., Scemama M., Schwartz G.G., Sijbrands E.J.G., Simoons M.L., Sinnaeve P.R., Sritara P., Steg P.G., Sy R.G., Szarek M., Tamby J.F., Tricoci P., Tse H.F., Tuñón J., Valgimigli M., Viigimaa M., Vogel R., White H.D., Xavier D., Yong H., Yusoff K., Zahger D., Zeiher A.M.